Collegeville, PA, United States of America

Peter F Lebowitz

This inventor holds 6 USPTO granted patents and 15 published patent applications, plus 1 CIPO patent and 9 EPO patents. Top assignees: Glaxosmithkline LLC, Novartis Ag. Active years: 2014-2020.

USPTO Granted Patents = 6 (Patent Applications = 15)

% Patents Active = 50.0

CIPO Patents = 1

EPO Patents = 9 (Patent Applications = 10)

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 34(Granted Patents)

Location History:

Collegeville, PA (US) (2014 - 2016)
Research Triangle Park, NC (US) (2020)

Company Filing History:

Years Active: 2014-2020

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10869869 - Method of adjuvant cancer treatment (2020-12-22),

2. 9402846 - Combination of inhibitor of B-Raf and inhibitor of AKT in the treatment of cancer (2016-08-02),

3. 8952018 - Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors (2015-02-10),

4. 8835450 - Combination of inhibitor of B-Raf and an inhibitor of Akt in the treatment of cancer (2014-09-16),

5. 8796298 - Combination of a B-Raf inhibitor: N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1- dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and the Akt inhibitor: N-{ (1S)-2-amino-1-[(3- fluorophenyl)methyl]ethyl}-5-chIoro-4-(4-chIoro- 1 -methyl- 1 H-pyrazol-5-yl)-2-10 thiophenecarboxamide useful in the treatment of cancer (2014-08-05),

6. 8703781 - Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors (2014-04-22),

Title: The Innovative Contributions of Peter F. Lebowitz

Introduction

Peter F. Lebowitz is a notable inventor based in Collegeville, PA (US). He has made significant contributions to the field of cancer treatment, holding a total of 6 patents. His work focuses on developing methods and pharmaceutical combinations that enhance the effectiveness of cancer therapies.

Latest Patents

Among his latest patents is a method of adjuvant cancer treatment. This invention provides a method for administering therapeutically effective doses of dabrafenib and trametinib to increase relapse-free survival in human patients. Another significant patent involves the combination of an inhibitor of B-Raf and an inhibitor of AKT in cancer treatment. This method includes administering specific pharmaceutical compounds to patients in need of effective cancer therapies.

Career Highlights

Peter has worked with prominent companies in the pharmaceutical industry, including GlaxoSmithKline LLC and Novartis AG. His experience in these organizations has contributed to his expertise in developing innovative cancer treatments.

Collaborations

Throughout his career, Peter has collaborated with talented professionals, including Sylvie Laquerre and Melissa Dumble. These collaborations have further enriched his research and development efforts in the field of oncology.

Conclusion

Peter F. Lebowitz's innovative work in cancer treatment exemplifies the impact of dedicated inventors in the medical field. His patents and collaborations continue to pave the way for advancements in cancer therapies.